The Disease Nobody Could Treat Just Got Its First Drug

The Data That Got It Across the Finish Line

The pivotal trial tested Zanvastro in patients aged 5 and older, using a simple but meaningful primary endpoint: gait speed, measured by a 10-meter walk test. Can you walk, and how fast?

At 61 weeks, treated patients saw their gait speed decline by just 2.1%. The control group? They dropped 35.4%. That's a 33.3 percentage-point difference, and it was statistically significant (p = 0.041). In a disease where walking ability erodes relentlessly, holding the line is a win.

For younger children aged 2 to 4, the trial used a gross motor function assessment instead, and Zanvastro improved those scores compared to controls. In an open-label substudy of children under 2, treated kids improved on motor assessments. Patient and caregiver-reported outcomes also generally favored the drug, though one secondary endpoint (most bothersome symptom) didn't reach statistical significance.

The safety profile was described as favorable across the trial program.

The Price Tag Nobody Blinked At

Zanvastro carries a list price of $285,000 per dose. With quarterly dosing, that works out to roughly $1.14 million per year before rebates or discounts.

When you're the only treatment for a progressive, often fatal disease with a tiny patient population, the usual pricing debates get quieter. There's no generic alternative to compare against. There's no "well, they could try the other drug" argument. This is it.

Why This Matters Beyond Alexander Disease

Approving a drug for 500-ish documented patients sends a powerful signal. The FDA is telling the biotech industry: we will greenlight therapies for extremely small populations if the science holds up.

The agency has been formalizing this approach. Its Rare Disease Evidence Principles framework allows approval based on a single well-controlled study plus strong confirmatory evidence when patient numbers are tiny. For ultra-rare genetic diseases with fewer than 1,000 U.S. patients and no alternatives, the FDA is explicitly saying that biomarker data, natural history studies, and mechanistic evidence can fill the gaps that traditional large-scale trials can't.

For Ionis specifically, this approval validates a bigger bet. The company has been building a wholly owned neurology pipeline of antisense therapies, and Zanvastro is the proof of concept. Next up is obudanersen for Angelman syndrome, currently in Phase 3 with data expected in the second half of 2027. Behind that sit programs targeting Dravet syndrome, prion disease, MECP2 duplication syndrome, Pelizaeus-Merzbacher disease, and multiple system atrophy. Ionis also maintains partnered CNS programs with Biogen, including tofersen for SOD1 ALS.

The thesis is straightforward: if you can design antisense drugs that precisely silence disease-causing genes in the brain, every rare neurological disease with a known genetic driver becomes a potential target.

Wall Street's Verdict: Cautious Optimism

Analysts are broadly positive. H.C. Wainwright reiterated Buy with a $100 price target. JPMorgan stayed Overweight at $76. Canaccord Genuity reiterated Buy at $95, emphasizing launch execution.

BMO Capital was the skeptic in the room, starting coverage at Market Perform with a $60 target. Their concern is about Ionis's transition to a self-commercialized model; making drugs and selling them are two very different skill sets.

The stock reaction has been somewhat muted, partly because investors are also digesting a separate cardiovascular trial miss from Ionis. One win doesn't erase all concerns.

The Bigger Picture

Somewhere, a family that was told "there's nothing we can do" just got a phone call from their neurologist. The conversation is different now.

That's what a first-in-disease approval means. Not just a commercial milestone for Ionis or a regulatory precedent for the FDA. A before and an after. For decades, Alexander disease had no "after." Now it does.